LLY

Eli Lilly & Co.

New York Stock Exchange

$230.8

Open: $228.86 High: $233.72 Low: $226.72 Close: $230.88

Range: 2021-09-20 - 2021-09-21

Volume:3,679,089

Market: Open

Get Free API Key

Download as Excel

LLY

Eli Lilly & Co. Lilly Corporate Center Indianapolis IN, 46285 http://www.lilly.com

Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

CEO: David A. Ricks
Employees: 40,655
Sector: Healthcare
Industry: Drug Manufacturers

Latest Stocks Posts

View All Posts >

LLY News

Latest news about the LLY

EU signs joint procurement deal for Eli Lilly COVID-19 treatment
The European Commission has signed a joint procurement contract with U.S. drugmaker Eli Lilly and Co for the supply of a monoclonal antibody treatment for COVID-19, the EU executive arm said in a statement on Tuesday. The treatment is under review by the European Medicines Agency, it said, and 18 EU countries have signed up to the joint procurement for the purchase of enough to treat up to 220,000 patients. The deal is part of a portfolio of five promising therapeutics announced by the Commission under the EU's COVID-19 Therapeutics Strategy in June.
View More →
UPDATE 1-Lilly to supply up to 220,000 COVID-19 antibody combo doses to European countries
Eli Lilly on Tuesday announced a pact with the European Commission to supply up to 220,000 doses of its COVID-19 dual antibody cocktail to European countries for patients aged 12 years and older who are at a high risk of progressing to severe disease. The agreement enables participating countries in the European Union and European Economic Area to purchase the products directly from Lilly, following authorization, Lilly said, adding that the quantities purchased may vary based on local needs. While a number of European countries have previously ordered bamlanivimab and etesevimab in the first half of the year and have inventory on hand, this agreement provides access to additional doses for participating countries, should they be needed, Lilly said.
View More →
Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19
Eli Lilly and Company (NYSE: LLY) today announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of confirmed COVID-19 in patients aged 12 years and older who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. This agreement helps to provide access to treatments by enabling participating countries in the European Union (EU) and European Eco
View More →
Do Eli Lilly's (NYSE:LLY) Earnings Warrant Your Attention?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
View More →
Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps for Its 3.950% Notes due 2049 and Its 4.150% Notes due 2059
Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its outstanding debt securities. Lilly also announced that it has removed the previously announced note caps setting forth the maximum principal amounts of its 4.150% Notes due 2059 and its 3.950% Notes due 2049 that Lilly will accept for purchase pursuant to the tender offer. Except as described in this press release, all other terms of the tender offe
View More →
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.
View More →
Is AbbVie a Bad News Buy?
The U.S. Food and Drug Administration recently announced restrictions on JAK inhibitors that hurt AbbVie's (NYSE: ABBV) prospects for autoimmune disease drug Rinvoq. AbbVie stock sank more than 10% after the FDA's decision. In this Motley Fool Live video recorded on Sept. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie stock is now a bad news buy.
View More →
Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail
FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.
View More →
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.
View More →
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis (PEP) in certain individuals for the prevention of SARS-CoV-2 infection, Eli Lilly and Company (NYSE: LLY) announced today. The neutralizing antibodies can now be used together to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not ex
View More →
UPDATE 1-FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus
The U.S. Food and Drug Administration said on Thursday it has revised its emergency use authorization for Eli Lilly's COVID-19 antibody cocktail to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease. However, the FDA said on Thursday the cocktail is not a substitute for vaccination against COVID-19. The FDA said that bamlanivimab and etesevimab, which are administered together, could be also used as post-exposure prevention for patients who are not fully vaccinated or who are not expected to mount an adequate immune response to complete vaccination or have been exposed to an individual infected with the virus.
View More →
FDA revises Lilly's COVID-19 antibody combo EUA for use after exposure to virus
The U.S. Food and Drug Administration said on Thursday it has revised its emergency use authorization for Eli Lilly's COVID-19 antibody cocktail to include for use after exposure to the virus in patients who are at high risk for progression to severe disease.
View More →
Regeneron, Lilly Get New COVID Drug Deals From Government
Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.
View More →
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW
Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.
View More →
After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly
The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19. Related Link: Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies. As part of the agreement, Lilly will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government. Approximately 200,000 doses will be shipped in Q3 2021, and the remaining to be shipped in Q4. This transaction is expe
View More →
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P
View More →
UPDATE 1-U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy
Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, as infections surge due to the fast-spreading Delta variant. The news comes after Regeneron Pharmaceuticals Inc said late on Tuesday the U.S. government was buying 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV. Lilly said its deal with the U.S government is expected to generate approximately $330 million in revenue in the second half of 2021, with about 200,000 doses expected to be shipped in the third quarter this year and the remaining in fourth.
View More →
Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million
Eli Lilly & Co. announced Wednesday to sell 388,000 doses of etesevimab, which has been authorized for emergency use as a COVID-19 treatment for $330 million. As part of the deal, about 200,000 doses of etesevimab, which complements doses of bamlanivimab previously purchased by the U.S. government, are expected to ship in the third quarter of 2021, with the remaining doses to be shipped in the fourth quarter. "The recent increase in COVID-19 cases has caused a substantial rise in the utilization
View More →
Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19
Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. As part of the agreement, Lilly will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government, with approximately 200,000 doses expected to ship Q3 2021 and the remaining to be shipped in Q4. This transaction is expected to generate approximately $
View More →
Top Research Reports for Eli Lilly, Exxon Mobil & Lowe's
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Exxon Mobil Corporation (XOM), and Lowe's Companies, Inc. (LOW).
View More →

LLY

LLY

Eli Lilly & Co. Lilly Corporate Center Indianapolis IN, 46285 http://www.lilly.com

Latest Stocks Posts

View All Posts >

LLY News

Latest news about the LLY

Request a consultation.

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader

LLY

LLY

Eli Lilly & Co. Lilly Corporate Center Indianapolis IN, 46285 http://www.lilly.com

Share LLY Stock Page

Latest Stocks Posts

View All Posts >

LLY News

Latest news about the LLY

The Top Decentralized Oracles in 2021

How Does the Stock Market Work?

How to become a good Quant Trader